BSTC Share Price

Open 45.84 Change Price %
High 46.21 1 Day -0.19 -0.41
Low 44.76 1 Week 0.00 0.00
Close 45.77 1 Month -1.77 -3.72
Volume 25898 1 Year -2.72 -5.61
52 Week High 58.79
52 Week Low 41.95
BSTC Important Levels
Resistance 2 47.11
Resistance 1 46.56
Pivot 45.58
Support 1 44.98
Support 2 44.43
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

BioSpecifics Technologies Corp (NASDAQ: BSTC)

BSTC Technical Analysis 5
As on 31st Oct 2017 BSTC Share Price closed @ 45.77 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 50.76 & Strong Sell for SHORT-TERM with Stoploss of 46.70 we also expect STOCK to react on Following IMPORTANT LEVELS.
BSTC Target for November
1st Target up-side 48.71
2nd Target up-side 50.77
3rd Target up-side 52.83
1st Target down-side 42.83
2nd Target down-side 40.77
3rd Target down-side 38.71
BSTC Other Details
Segment EQ
Market Capital 101002608.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biospecifics.com
BSTC Address
BSTC
35 Wilbur Street
Lynbrook, NY 11563
United States
Phone: 516-593-7000
Fax: 516-593-7039
BSTC Latest News
Interactive Technical Analysis Chart BioSpecifics Technologies Corp ( BSTC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on BioSpecifics Technologies Corp
BSTC Business Profile
BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase (which Auxilium has named XIAFLEX) for clinical indications in Dupuytren’s contracture, Peyronie’s disease and frozen shoulder (adhesive capsulitis), and Auxilium has an option to acquire additional indications that it may pursue, including lipomas and cellulite. Auxilium has an agreement with Pfizer, Inc. (Pfizer), pursuant to which Pfizer has the right to market XIAFLEX for Dupuytren’s contracture and Peyronie’s disease in 27 member countries of the European Union and 19 other European and Eurasian countries, and under the registered trademark XIAPEX (collagenase clostridium histolyticum).